New Novartis AG (NVS) Heart Drug Might Achieve Blockbuster Status
4/2/2014 8:02:39 AM
I try to avoid using words like “blockbuster” and “breakthrough” when writing about new drugs and treatments. I’ve been disappointed too many times. But, though they’ve been in short supply lately in cardiovascular medicine, sometimes there really are breakthroughs and blockbusters. In my career writing about cardiovascular medicine I’ve seen the introduction of the ACE inhibitors, statins, stents, ICDs, and clopidogrel, among others. All of these became multibillion-dollar products and, more importantly, vastly improved the prospects for millions of people with cardiovascular disease.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by